EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
The day's agenda is now available for the upcoming 2019 EUnetHTA Forum on 11th April at the West-Indisch Huis in central Amsterdam. We are looking forward to hosting a collaborative, informative session of talks that both outline progress made in European
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
PTJA04 Final Project Plan – Sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues
Please see the below Final Project Plan of the Fourth Pharma Joint Assessment on 'sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues.' Timelines will change slightly due to the